12.09.2017

Pavol Cekan, co-founder and CEO of MultiplexDX, the cancer diagnostics company from the Neulogy Ventures' investment portfolio, in an interview for leading scientific publisher Elsevier. Read the full article on MultiplexDX's mission to creating reliable, 100% accurate and affordable diagnostics for cancer.